Congo to receive 70,000 doses of Ervebo Ebola vaccine which has been effective in past outbreaks

edited by Andrew Zinin

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process
Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

reputable news agency

proofread

The GIST Add as preferred source

Congo will receive 70,000 doses of the Ervebo vaccine, which has been effective in past Ebola outbreaks, the World Health Organization and partners said Thursday, announcing a step seen as a major boost to efforts to contain what officials have described as the fastest Ebola outbreak in history.

The Ervebo vaccine is licensed for use against Ebola virus, one of the viruses that cause Ebola disease, but not for Bundibugyo virus, which is responsible for the current outbreak which has so far killed 2,476 people out of the 5,208 confirmed cases.

WHO said in a statement that while it's not known whether Ervebo may protect against the Bundibugyo virus, "early laboratory and animal data suggest it may provide some protection."

The allocation includes 20,000 doses for a Phase 3 clinical trial to understand the impact of the vaccine on the Bundibugyo virus, the agency said. The remaining 50,000 doses will be used for front-line and health workers as recommended by WHO experts.

The outbreak raging in six provinces in eastern Congo has infected and killed more people at a greater speed than any other Ebola outbreak in history, and is spreading about three times faster compared to the 2014-2016 outbreak across West Africa — the deadliest Ebola outbreak on record with more than 11,000 deaths.

The International Coordinating Group on Vaccine Provision, which includes WHO and other partners, said the doses will be released immediately following a request from Congo's government.

WHO Director-General Tedros Adhanom Ghebreyesus called the approval "an important example of global solidarity in action." He said the agency and its partners remain committed to supporting strengthened surveillance, rapid detection, quality care, community engagement and vaccination efforts to bring the outbreak under control.

The lack of approved vaccines or treatments for the rare Bundibugyo virus has been a major issue for responders. Most new cases have been reported outside of the people being monitored, showing the virus continues to spread faster than efforts to track it. That has been a key contributor to the recorded deaths.

The case fatality rate so far is 47.5% although it is far worse in some places where response efforts are more challenging, such as in North Kivu province where the fatality rate is up to 70%.

Experts believe the virus began spreading from the mining town of Mongbwalu as early as February, months before authorities declared the outbreak on May 15.

Key medical concepts

Ebola virusCase Fatality Rates

Clinical categories

Infectious diseasesCommon illnesses & PreventionClinical pharmacology Who's behind this story?

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

© 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: Congo to receive 70,000 doses of Ervebo Ebola vaccine which has been effective in past outbreaks (2026, August 20) retrieved 20 August 2026 from https://medicalxpress.com/news/2026-08-congo-doses-ervebo-ebola-vaccine.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.